G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 127 filers reported holding G1 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,792 | -74.1% | 6,800 | -55.3% | 0.00% | -50.0% |
| Q2 2023 | $37,848 | +1.6% | 15,200 | +9.4% | 0.00% | -33.3% |
| Q1 2023 | $37,252 | -76.5% | 13,900 | -52.4% | 0.00% | -72.7% |
| Q4 2022 | $158,724 | +2545.4% | 29,231 | +5253.7% | 0.01% | – |
| Q3 2022 | $6,000 | -95.3% | 546 | -97.9% | 0.00% | -100.0% |
| Q2 2022 | $129,000 | +4200.0% | 26,287 | +6891.2% | 0.01% | – |
| Q4 2021 | $3,000 | -98.1% | 376 | -96.8% | 0.00% | -100.0% |
| Q3 2021 | $157,000 | +3825.0% | 11,715 | +5323.6% | 0.01% | – |
| Q2 2021 | $4,000 | -66.7% | 216 | -70.0% | 0.00% | -100.0% |
| Q4 2020 | $12,000 | +20.0% | 720 | -17.7% | 0.00% | 0.0% |
| Q3 2020 | $10,000 | -93.6% | 875 | -85.3% | 0.00% | -93.8% |
| Q4 2019 | $157,000 | +234.0% | 5,950 | +186.3% | 0.02% | +220.0% |
| Q3 2019 | $47,000 | -21.7% | 2,078 | +78.7% | 0.01% | +25.0% |
| Q3 2018 | $60,000 | +566.7% | 1,163 | +438.4% | 0.00% | +300.0% |
| Q2 2018 | $9,000 | -87.1% | 216 | -88.6% | 0.00% | -83.3% |
| Q1 2018 | $70,000 | – | 1,890 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 994,287 | $19,041,000 | 1.55% |
| HHLR ADVISORS, LTD. | 949,431 | $18,182,000 | 0.75% |
| BB BIOTECH AG | 671,925 | $12,867,000 | 0.41% |
| Rhenman & Partners Asset Management AB | 172,820 | $3,310,000 | 0.38% |
| Birchview Capital, LP | 15,000 | $287,000 | 0.27% |
| Rock Springs Capital Management LP | 100,000 | $1,915,000 | 0.09% |
| SECOR Capital Advisors, LP | 32,591 | $624,000 | 0.08% |
| MARSHALL WACE, LLP | 386,510 | $7,402,000 | 0.08% |
| SIGNATUREFD, LLC | 37,942 | $727,000 | 0.07% |
| A.R.T. Advisors, LLC | 38,125 | $730,000 | 0.05% |